“Though VEGFR-2 is a known target for anti-cancer therapy, clinical use of VEGFR-2 inhibitors has been challenged by limited efficacy and various side effects, potentially due to low selectivity ...

About VEGFR-2/TIE 2 VEGFR-2/TIE 2, now known as TRPH 011, is a novel, first-in-class, fully human bi-specific antibody that binds and neutralizes VEGFR-2/KDR and TIE 2 receptors simultaneously ...

In the MARC-2-study, pts treated with everolimus will be characterized by serum and tissue biomarkers in order ... Major inclusion criteria are confirmed predominantly clear cell mRCC, failure of ...

Previous phase II data with a VEGFR TKI demonstrated improved progression-free survival (PFS) in patients with relapsed or refractory soft tissue sarcoma. Tivozanib is a potent and highly selective ...